



## Newbury Pharmaceuticals is strengthening its portfolio and strategic focus

**Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with additional seven (7) oncology products; Nintedanib, Palbociclib, Pomalidomide, Nilotinib, Enzalutamide, Lenvatinib, Bosutinib.**

*“The products are a terrific supplement to the existing high-value product portfolio and we are proud to strengthen our commitment within oncology”, says Mr. Lars Minor, CEO of Newbury.*

Newbury currently has ten (10) products within oncology and is providing treatment options for both solid and hematological malignancies (e.g. breast cancer, myeloma, leukemia, prostate cancer, NSCLC and thyroid cancer).

Regulatory filling will take place during the next few years, and we aim to be among the first to launch many of these medicines in Scandinavia where the total annual value of this market is estimated to be 400 MEUR according to DLMI Nordic Pharma Insights.

*“Newbury is a start-up with high ambitions and we are rapidly growing our portfolio within our focus areas of oncology, rare diseases and neurology. We want to be known to make a difference within these therapeutic areas”, says Karl Karlsson, Founder & Chairman.*

### **For more information, contact:**

---

Lars Minor, CEO  
[lars.minor@newburypharma.com](mailto:lars.minor@newburypharma.com)  
Mobile: +46 72-377 3005

[www.newburypharma.com](http://www.newburypharma.com)

### **About Newbury Pharmaceuticals**

---

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury Pharmaceuticals wants to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging its experience and extensive international network whereby Newbury can offer strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Press Release  
21 October 2021 11:30:00 CEST



## Attachments

---

[Newbury Pharmaceuticals is strengthening its portfolio and strategic focus](#)